Genmab A/S
NASDAQ:GMABBiotechnology
-$0.12 today
- Market cap
- $31.43B
- Beta
- 0.68
- P/E (TTM)
- 18.7
- EPS (TTM)
- $13.36
Volume 2.96M
Average 1.85M
GMAB Debt Repayment
Cash used to repay borrowings during the period.
Genmab A/SNASDAQ: GMAB
Debt Repayment · Q2 FY2026 · quarter ended Jun 2026
Debt repayment grows 1525.3% year over year
Q2 FY2026 debt repayment of $65M (cash outflow) rose 1525.3% year over year. Sequentially, it fell 5.8% from the prior quarter.
Context
- Debt repayment amounted to 140.5% of revenue in FY2025, up 140.2 pp from a year earlier.
- Debt repayment increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
Mixed currencies · from the cash flow
- Latest · FY2025
- 5.23B USD
- Year-over-year change
- —
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.23B | — |
| FY2024 | 2024-12-31 | (60M) | +34.1% |
| FY2023 | 2023-12-31 | (91M) | -24.7% |
| FY2022 | 2022-12-31 | (73M) | -25.9% |
| FY2021 | 2021-12-31 | (58M) | — |
Debt Repayment vs competitors
How GMAB compares with its peers on the latest reported figures
- Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
- Debt repayment amounts to 3.4% of revenue for GMAB, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $139.31M USD | — | — | 3.4% | |
| LTM Jun 2026 | €68.06M EUR | +862.0% | -43.2% | 2.6% | |
| LTM Sep 2026 | $50.6M USD | +1314.2% | — | 3.7% | |
| LTM Jun 2026 | $4.64M USD | +8.9% | +16.7% | 0.1% | |
| LTM Mar 2026 | $2.67M USD | +178.3% | — | — | |
| LTM Jul 2026 | $0 USD | — | — | 0.0% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | -100.0% | — | 0.0% | |
| LTM Dec 2025 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding GMAB) | — | +178.3% | -13.2% | 0.0% | |
Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · DKK | FY2022 Dec 2022 · DKK | FY2023 Dec 2023 · DKK | FY2024 Dec 2024 · DKK | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | 3.98B | 7.04B | 5.64B | 7.84B | 963.76M |
| Depreciation & Amortization | 248.99M | 362M | 293.62M | 413M | 71.06M |
| Deferred Income Tax | (546M) | 0 | 122M | 0 | 0 |
| Stock-Based Compensation | 310M | 439M | 586M | 721M | 0 |
| Change in Working Capital | (770M) | (1.93B) | 1.36B | (1.6B) | 225.18M |
| Accounts Receivables | (1.07B) | (2.12B) | 797M | (1.59B) | (166.13M) |
| Inventory | 0 | 0 | (57M) | (5M) | (9.01M) |
| Accounts Payables | 304M | 283M | 622M | 0 | 400.32M |
| Other Working Capital | 0 | (90M) | 0 | 0 | 0 |
| Other Non-Cash Items | (997.99M) | (1.99B) | (620.62M) | 388M | (73.06M) |
| Operating Cash Flow | 2.23B | 3.91B | 7.38B | 7.77B | 1.19B |
| Capital Expenditures | (252M) | (317M) | (376M) | (187M) | (37.03M) |
| Acquisitions (Net) | 709M | 2.44B | 0 | (12.25B) | (7.22B) |
| Purchases of Investments | (15.62B) | (9.7B) | (10.91B) | (8.64B) | (995.78M) |
| Sales of Investments | 14.91B | 7.25B | 10B | 11.28B | 2.62B |
| Other Investing Activities | (709M) | (2.44B) | (10M) | (117M) | 0 |
| Investing Cash Flow | (961M) | (2.76B) | (1.28B) | (9.91B) | (5.65B) |
| Debt Repayment | (58M) | (73M) | (91M) | (60M) | 5.23B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 23.02M |
| Common Stock Repurchased | (447M) | (908M) | (564M) | (3.99B) | (430.34M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 85M | 192M | 49M | 129M | (31.02M) |
| Financing Cash Flow | (420M) | (789M) | (606M) | (3.92B) | 4.79B |
| Effect of Forex Changes | 850M | 574M | (518M) | 1.05B | 13.06M |
| Net Change in Cash | 1.7B | 936M | 4.97B | (5.01B) | 345.33M |
| Free Cash Flow | 1.98B | 3.6B | 7B | 7.58B | 1.15B |
Genmab A/S
NASDAQ:GMAB
Intrinsic Alpha fair value
Locked
Current Price
$50.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.